News by subject: TRI

Subcutaneous (SC) injection offers an alternative administration option to intravenous (IV) infusion, with the opportunity to provide greater flexibility and convenience for patients, healthcare providers, and healthcare systems in how cancer...

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on...

This award recognizes Clario's commitment to delivering the levels of excellence and innovation required to ensure data integrity in clinical trials. Clario receives award for its broad endpoint technology solutions and scientific expertise, which...

Neurocrine Biosciences, Inc. , today announced positive topline data for its Phase 2 SAVITRItm study. This randomized, double-blind, placebo-controlled...

Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global...

HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed  Pre-A and Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by...

PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today that the Company's U.S. subsidiary, Wincal Biopharm, Inc....

SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on its novel Gene Codingtm technology, today announced that four abstracts, including one oral presentation, will be...

ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced that it will present new ex vivo...

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that new...

Bolt Medical, Inc., a clinical stage medical device company is developing a new generation intravascular lithotripsy (IVL) advanced laser-based platform with inherent advantages over commercially available IVL devices for the treatment of calcified...

Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s)...

Trialize (https://trialize.io) is proud to unveil the Trial Data Object Model (TDOM), an innovative open-source framework designed to enhance interoperability among various e-clinical systems. Tailored for clinical trials, TDOM aims to standardize...

Actinogen Medical Limited  announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept,...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for...

MSBAI, an Air Force Techstars 2020 company, today announced the successful completion of its AFWERX Phase 2 SBIR contract, titled GURU Owns the Modeling and Simulation Tech Stack. This milestone represents a significant advancement in the U.S. Air...

TrialSite News features a paper published today in Viruses (Basel), authored by an international team of researchers, including two fellows of their nations' academies of sciences (Colleen Aldous, senior author Wendy Hoy) and others who participated...

"This groundbreaking system has been clinically proven to improve a patient's quality of life, reduce daytime sleepiness and minimize the overall number of disrupted breathing events," said Dr. Dan Shade, AHN Center for Sleep MedicineKey Takeaways:...

Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, today announced that patients have successfully received HYALEX Knee Implants as part of the...

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1 Evaluating over 40 MTAP PDX...

Hyundai Bioscience (KOSDAQ 048410) announced the positive results from its preclinical study on triple-negative breast cancer, investigating combination...

Immunovia , the diagnostics company with the mission to increase pancreatic cancer survival through early detection, today?announces its next-generation pancreatic cancer test achieved both the primary and secondary endpoints in a model-development...

Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the China phase II clinical trial (the "Phase II Clinical Trial") of...

Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

Today at ACP's annual meeting, Internal Medicine Meeting 2024, Annals of Internal Medicine presented three breaking scientific research articles during a live scientific plenary session that featured the authors of those articles. The articles were...

For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely. Not only can these injuries lead to a loss of...

Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that the company will be...

Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

Partner Therapeutics, Inc. (PTx) announced publication of a comprehensive review by Dougan et al.1 in Cancers summarizing the mechanistic rationale and pre-clinical and clinical data regarding the use of Leukine (sargramostim; glycosylated,...

On Wednesday, Interventional Pain Management Physician Raj Sureja, MD, performed the first sacroiliac (SI) joint fusion in Virginia, Maryland, and DC, using the PainTEQ LinQ SI Joint Stabilization System. https://www.painteq.com/procedure This...

What: In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person's cancer will respond to a...

A new study by surgeon-scientists at Hospital for Special Surgery (HSS) found that 25% of patients with hip impingement who underwent modern arthroscopy for their condition experienced a delay in the natural progression of osteoarthritis. The...

Researchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains that closely mirror the one recently detected in cows,...

GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign...

D2M...

D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating  Immunological-Inflammatory diseases and cancers,   today announced that the first patient had been dosed in a phase 1,...

...

?     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through...

In this free webinar, review and understand the transformative impact of a biomarker-driven approach to identify sub-populations in clinical trials. Attendees will discover how artificial intelligence (AI) can expedite the analysis of clinical data...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session...

?     Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects in a European clinical trial ?     There are...

Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced an oral presentation on RBT-1 at the prestigious, invitation only,...

YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

Two major presentations collectively representing the largest real-world data...

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia --...

GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck...